Drugs for Alzheimer's disease

Editorial

J T O'Brien et al. BMJ. 2001.

. 2001 Jul 21;323(7305):123-4.

doi: 10.1136/bmj.323.7305.123.

No abstract available

Comment in

Drugs for Alzheimer's disease. More effective agents are needed.
Warner J, Butler R. Warner J, et al. BMJ. 2001 Nov 10;323(7321):1127-8. BMJ. 2001. PMID: 11725755 Free PMC article. No abstract available.
Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK.
Noble JM. Noble JM. BMJ. 2001 Nov 10;323(7321):1128. BMJ. 2001. PMID: 11725756 No abstract available.

1. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol. 1991;20:736–748. - PubMed
1. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) Psychol Med. 1998;28:319–335. - PubMed
1. Audit Commission. Forget me not. Portsmouth: Holbrooks; 2000.
1. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;ii:1457–1459. - PMC - PubMed
1. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136–145. - PubMed